(94 days)
For in vitro diagnostic use only. VITROS dHDL Slides are used to quantitatively measure HDL cholesterol (HDLC) concentration in serum and plasma. High Density Lipoprotein (HDL) cholesterol is used to evaluate the risk of developing coronary heart disease (CHD). The risk of CHD increases with lower HDL cholesterol concentrations.
For in vitro diagnostic use. VITROS Chemistry Products Calibrator Kit 25 is used to calibrate VITROS Chemistry Systems for the quantitative measurement of HDL cholesterol using VITROS Chemistry Products dHDL Slides.
For in vitro diagnostic use only. VITROS Chemistry Products Performance Verifiers I and II are assayed controls used to monitor performance on VITROS Chemistry Systems.
The VITROS Chemistry Systems are fully automated clinical chemistry analyzers intended for use in the in vitro determination of various analytes in human specimens (serum, plasma, urine, and cerebrospinal fluid).
The system is comprised of four main elements:
- The VITROS Chemistry System - instrumentation, which provides automated use of the chemistry reagents.
- The VITROS Chemistry Products MicroSlides range of products, in this case the VITROS Chemistry Products dHDL Slides, VITROS Chemistry Products Calibrator Kit 25 and VITROS Chemistry Products Performance Verifier I and II which are combined by the VITROS Chemistry Systems to perform the VITROS dHDL Slide assay.
- The VITROS Chemistry Products MicroTip range of liquid reagent products that are formulated for use only on the VITROS 5,1 FS Chemistry System.
- Common reagents used by multiple assays on the VITROS Chemistry Systems, in this case VITROS Chemistry Products 7% BSA.
The VITROS System and reagents are designed specifically for use with the VITROS Chemistry Products range of products.
The provided document is a 510(k) summary for in-vitro diagnostic devices (VITROS Chemistry Products dHDL Slides, Calibrator Kit 25, and Performance Verifiers I and II) and therefore does not include the detailed acceptance criteria and study information typically found for AI/ML-driven medical devices. The document focuses on demonstrating substantial equivalence to a predicate device.
However, I can extract the information provided regarding the comparison study.
Here's a breakdown of the available information based on your request categories:
1. A table of acceptance criteria and the reported device performance:
The document doesn't explicitly state "acceptance criteria" in the way an AI/ML study would (e.g., target specificity, sensitivity thresholds). Instead, it relies on demonstrating substantial equivalence to a predicate device. The performance is reported as a correlation between the new device and the predicate device.
| Metric (New Device vs. Predicate Device) | Reported Value |
|---|---|
| Linear Regression Coefficient (slope) | 0.953 |
| Linear Regression Intercept | -0.64 mg/dL |
| Correlation Coefficient (r) | 0.996 |
2. Sample size used for the test set and the data provenance:
- Sample Size: The document states that "patient samples" were used, but the specific number is not provided.
- Data Provenance: Not specified (e.g., country of origin).
- Retrospective/Prospective: Not specified.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
This information is not applicable as this is an in-vitro diagnostic device measuring HDL cholesterol. The "ground truth" would be established by reference methods or comparison to the predicate device, not by expert interpretation of images or other subjective data. No experts for ground truth establishment are mentioned.
4. Adjudication method for the test set:
Not applicable for this type of device. The comparison is between quantitative measurements from two different analytical systems.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
Not applicable. This is an in-vitro diagnostic assay, not an AI-assisted diagnostic tool that would involve human readers interpreting results.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
The device is a standalone in-vitro diagnostic assay. Its performance is evaluated intrinsically and through comparison to the predicate device. It operates without human-in-the-loop performance in the interpretative sense of AI.
7. The type of ground truth used:
The "ground truth" for this study is essentially the quantitative measurement of HDL cholesterol obtained from the predicate device, the AHDL Flex® reagent cartridge for use with the Dade Behring Dimension® analyzer. The study aims to show that the new device's measurements are highly correlated with those of the predicate device.
8. The sample size for the training set:
The document describes a comparison study, not a machine learning study with distinct training and test sets in the typical sense. Therefore, "training set" is not applicable in this context. The study utilized patient samples for the correlation analysis.
9. How the ground truth for the training set was established:
Not applicable, as there's no "training set" in the context of an ML model. The comparison is against the predicate device's measurements.
{0}------------------------------------------------
Page 1 of 75
OCT 2 8 2004
3.0 510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is: K042006
Submitter name, address, contact 3.1
Ortho-Clinical Diagnostics, Inc. 100 Indigo Creek Drive Rochester, New York 14626-5101 Phone: (585) 453-4253 Fax: (585) 453-3368
Contact Person: Darlene J. Phillips
3.2 Date of Preparation:
July 23, 2004
| 3.3 Device Proprietary Names: | |
|---|---|
| Trade Names | VITROS Chemistry Products dHDL Slides |
| VITROS Chemistry Products Calibrator Kit 25 | |
| VITROS Chemistry Products Performance Verifiers I and II | |
| Common Name | HDL Cholesterol assay |
3.4 Classification Names
Classification Name: Lipoprotein test system (862.1475): Class: I: The Clinical Chemistry and Toxicology Panel of the FDA has placed lipoprotein test systems in Class I. Since this device is an in vitro device intended for use in assessing the risk of cardiovascular diseases, it meets the reserved criteria under Section 510(l) of the Food, Drug, and Cosmetic Act.
Classification Name: Calibrator (862.1150): Class II The Clinical Chemistry and Toxicology Panel of the FDA has placed calibrators in Class II.
Classification Name: Quality Control material (assayed and unassayed) (862.1660): Class 1: The Clinical Chemistry and Toxicology Panel of the FDA has placed Quality Control material (assayed and unassayed) for clinical chemistry in Class I. Since this device is an assayed control, it meets the reserved criteria under Section 510(1) of the Food, Drug, and Cosmetic Act.
Continued on next page
{1}------------------------------------------------
page 2 75
Predicate device 3.5
- The VITROS Chemistry Products dHDL Slides and VITROS Chemistry Products 3.5.1 Calibrator Kit 25 are substantially equivalent to the Automated HDL Cholesterol (AHDL) Flex® reagent cartridge for use with the Dade Behring Dimension® analyzer.
- 3.5.2 The VITROS Chemistry Products Performance Verifiers I and II are substantially equivalent to the VITROS Chemistry Products Performance Verifiers I and II.
3.6 Device description
The VITROS Chemistry Systems are fully automated clinical chemistry analyzers intended for use in the in vitro determination of various analytes in human specimens (serum, plasma, urine, and cerebrospinal fluid).
The system is comprised of four main elements:
The VITROS Chemistry System - instrumentation, which provides automated use 1. of the chemistry reagents. The VITROS Chemistry Systems were cleared for market by separate premarket notifications:
VITROS 250/250AT Chemistry Systems (K922072 cleared July 10, 1992) VITROS 950/950AT Chemistry Systems (K946090 cleared January 17, 1995) VITROS 5,1 FS Chemistry System (K031924 cleared August 7, 2003)
The VITROS Chemistry Products MicroSlides"M range of products, in this case the 2. VITROS Chemistry Products dHDL Slides, VITROS Chemistry Products Calibrator Kit 25 and VITROS Chemistry Products Performance Verifier I and II which are combined by the VITROS Chemistry Systems to perform the VITROS dHDL Slide assay.
The VITROS Chemistry Products MicroTip™ range of liquid reagent products that 3. are formulated for use only on the VITROS 5,1 FS Chemistry System. The VITROS Chemistry Products dHDL Reagent and VITROS Chemistry Products Calibrator Kit 19 were cleared for market by premarket notification K031924, August 7, 2003; further VITROS MicroTip assays will be submitted under separate 510(k) submissions, as required.
- Common reagents used by multiple assays on the VITROS Chemistry Systems, in this case VITROS Chemistry Products 7% BSA (K903071 cleared September 27, 1990).
The VITROS System and reagents are designed specifically for use with the VITROS Chemistry Products range of products.
Continued on next page
{2}------------------------------------------------
page 3 of 5
Device intended use 3.7
VITROS Chemistry Products dHDL Slides 3.7.1
For in vitro diagnostic use only. VITROS Chemistry Products dHDL Slides are used to quantitatively measure HDL cholestero! (HDLC) concentration in serum and plasma. High Density Lipoprotein (HDL) cholesterol is used to evaluate the risk of developing coronary heart disease (CHD). The risk of CHD increases with lower HDL cholesterol concentrations.
VITROS Chemistry Products Calibrator Kit 25 3.7.2
For in vitro diagnostic use. VITROS Chemistry Products Calibrator Kit 25 is used to calibrate VITROS Chemistry Systems for the quantitative measurement of HDL cholesterol using VITROS Chemistry Products dHDL Slides.
3.7.3 VITROS Chemistry Products Performance Verifiers I and II
For in vitro diagnostic use only. The VITROS Chemistry Products Performance Verifiers I and II are assayed controls used to monitor performance on VITROS Chemistry Systems.
3.8 Comparison to predicate device
- 3.8.1 The VITROS Chemistry Products dHDL Slide and VITROS Chemistry Products Calibrator Kit 25 are substantially equivalent to the AHDL Flex reagent cartridge assay on the Dimension system (predicate device) which was cleared by the FDA (K032798) for IVD use.
The relationship between the VITROS dHDL Slides assay and the predicate device, determined by the least squares linear regression is:
VITROS dHDL Slides assay = 0.953 x X - 0.64 mg/dL,
with a correlation coefficient of 0.996,
where X is the AHDL Cholesterol assay on the Dade Dimension clinical chemistry analyzer.
In addition to the above mentioned correlation study, studies were performed to determine the precision, analytical sensitivity, specificity and expected values of the VITROS dHDL Slides assay, (refer to VITROS dHDL Slides Instructions For Use for summaries of the results of these studies).
Continued on next page
{3}------------------------------------------------
page 475
- Table 1 lists the characteristics of the VITROS dHDL Slides assay (new device) and the Table 1 AHDL Cholesterol assay (predicate device).
| DeviceCharacteristic | VITROS dHDL Slide assay(New Device) | Dimension AHDL assay(Predicate Device) |
|---|---|---|
| Reportable Range | 5.0 - 110.0 mg/dL | 0 - 150 mg/dL |
| Specimen Pretreatment | None Required:Homogeneous direct assay | None Required:Homogeneous direct assay |
| Basic principle | Precipitation and partitioning of non-HDL lipoproteins, followed bydetergent solubilization of HDLfollowed by enzyme-coupledcolorimetric quantitation of residualcholesterol in HDL fraction, in aself-contained solid state reagentcarrier | Polyanion complexing of non-HDLlipoproteins, accompanied bydetergent solubilization of HDLfollowed by enzyme-coupledcolorimetric quantitation of residualcholesterol in HDL fraction |
| Reagents | Dry chemistry, ready to use | Liquid reagents, ready to use |
| Test Type | Colorimetric endpoint | Bichromatic endpoint |
| Instrumentation | VITROS Chemistry Systems | Dade Dimension clinical chemistrysystems |
| Sample type | Serum, heparin plasma, and EDTAplasma | Serum and plasma |
| Sample volume | 10 µL | 3 µL |
| Reaction steps | Step 1: Precipitation of non-HDLlipoproteinsStep 2: Detergent solubilization ofHDLStep 3: Measurement | Step 1: Polyanion complexing ofnon-HDL lipoproteinsStep 2: Detergent solubilization ofHDLStep 3: Measurement |
| Incubation Temperature | 37°C | 37°C |
{4}------------------------------------------------
pages 95
- 3.8.2 The VITROS Chemistry Products Performance Verifiers I and II are substantially equivalent to the VITROS Chemistry Products Performance Verifiers (predicate device) which were cleared by the FDA (K904768) for IVD use.
- Table 2 lists the similarities and differences of the device characteristics between the Table 2 VITROS Performance Verifiers with the predicate device, VITROS Performance Verifiers I and II.
| DeviceCharacteristic | New device | Predicate device |
|---|---|---|
| Intended Use | VITROS Performance Verifier is anassayed control used to monitorperformance on VITROS ChemistrySystems. (New additional intendeduse: to monitor performance ofVITROS dHDL Slides assay on theVITROS Chemistry Systems.) | VITROS Performance Verifier isan assayed control used tomonitor performance on VITROSChemistry Systems. |
| Matrix of PerformanceVerifiers | A base matrix of freeze-dried humanserum to which enzymes.electrolytes, stabilizers, preservativesand other organic analytes have beenadded. | A base matrix of freeze-driedhuman serum to which enzymes,electrolytes, stabilizers,preservatives and other organicanalytes have been added. |
| Performance Verifier Levels | Low and High | Low and High |
3.9 Conclusions
The data presented in the premarket notification provide a reasonable assurance that the VITROS dHDL Slides assay and the VITROS Chemistry Products Performance Verifiers are safe and effective for the stated intended uses and are substantially equivalent to the cleared predicate devices. The data in this premarket notification demonstrate that the performance of the VITROS dHDL Slides assay and Performance Verifiers are substantially equivalent to the cleared predicate devices.
Equivalence to the predicates was demonstrated using commercially available reagents along with patient samples.
{5}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/5/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is a stylized image of three human figures, possibly representing a family, with their arms raised in a gesture of support or unity.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
OCT 2 8 2004
Ms. Darlene J. Phillips Regulatory Associate Ortho-Clinical Diagnostics, Inc. 100 Indigo Creek Drive Rochester, NY 14626
Re: K042006
Trade/Device Name: VITROS Chemistry Products dHDL Slides VITROS Chemistry Products Calibrators Kit 25 VITROS Chemistry Products Performance Verifiers I and II Regulation Number: 21 CFR 862.1475 Regulation Name: Lipoprotein test system Regulatory Class: Class I Product Code: LBS, JIS, JJY Dated: October 4, 2004 Received: October 5, 2004
Dear Ms. Phillips:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
{6}------------------------------------------------
Page 2
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours.
Stain M. Cooper, US, DVM.
Jean M. Cooper, MS, D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{7}------------------------------------------------
1.0 Indications for Use
| 510(k) Number (if known): | K042006 |
|---|---|
| Device Name: | VITROS Chemistry Products dHDL SlidesVITROS Chemistry Products Calibrator Kit 25VITROS Chemistry Products Performance Verifiers I and II |
| Indications for Use: | For in vitro diagnostic use only. VITROS dHDL Slides are used toquantitatively measure HDL cholesterol (HDLC) concentration in serum andplasma. High Density Lipoprotein (HDL) cholesterol is used to evaluate therisk of developing coronary heart disease (CHD). The risk of CHD increaseswith lower HDL cholesterol concentrations.For in vitro diagnostic use. VITROS Chemistry Products Calibrator Kit 25 isused to calibrate VITROS Chemistry Systems for the quantitativemeasurement of HDL cholesterol using VITROS Chemistry Products dHDLSlides.For in vitro diagnostic use only. VITROS Chemistry Products PerformanceVerifiers I and II are assayed controls used to monitor performance onVITROS Chemistry Systems. |
| Prescription Use(Part 21 CFR 801 Subpart D) | |
| AND/OR | Over-The-Counter Use(21 CFR 807 Subpart C) |
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Division Sign Off
Office of In Vitro Diagnostic
Device Evaluation and Safety
510/k) _______________________________________________________________________________________________________________________________________________________________________
Page 1 of 1
§ 862.1475 Lipoprotein test system.
(a)
Identification. A lipoprotein test system is a device intended to measure lipoprotein in serum and plasma. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.